Apogee Therapeutics(Apge) Financials: Equity Multiplier Compared To Industry Average, Plus Other Key Ratios
Solvency Trend (Last 5 Years)
Solvency - equity multiplier
This chart shows the historical trend of equity multiplier for APGE compared to its industry average over the recent years.
Ratio Definition and Interpretation
Name: Equity Multiplier
Definition: The equity multiplier shows how much total assets the company controls for every dollar invested by shareholders. It reflects how much debt is being used to stretch owners’ equity. A higher multiplier means greater use of debt to amplify returns — but also amplifies risk if things go wrong. Lower multipliers suggest a safer, more self-funded business.
Interpretation:
• In '2023', APGE's equity multiplier was 1.06, representing the level of financial leverage utilized. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2023' stood at 1.29.
• In '2024', APGE's equity multiplier was 1.05, representing the level of financial leverage utilized. The decrease since '2023' reflects improving financial health. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2024' stood at 1.14. Industry average declined by 0.15 from previous year.
Overall, APGE's equity multiplier has remained generally stable over the past 2 years.
Formula: Equity Multiplier = Total Assets / Shareholders' Equity
Good Range: Usually ranges from 1.5 to 3 depending on industry.